|Bid||5.90 x 4000|
|Ask||6.53 x 1400|
|Day's Range||6.24 - 6.55|
|52 Week Range||4.07 - 12.65|
|Beta (5Y Monthly)||0.93|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Taiwan Liposome Company, Ltd. Unsponsored ADR (TLC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
India's Central Drugs Standard Control Organization has approved Taiwan Liposome Company's (NASDAQ: TLC) marketing application for Amphotericin B Liposome for 50mg Injection for immediate import to aid in the country's emergency of acute liposomal amphotericin B shortage. AmphoTLC is a liposomal amphotericin B injection indicated for severe systemic fungal infections such as mucormycosis, a serious fungal infection known as a black fungus. With a high number of COVID-19 infections in India, the number of COVID-19 associated mucormycosis (CAM) cases has also been rising. Yesterday, TLC's subsidiary InspirMed Inc presented data on the potential advantages of inhalable liposome formulations that can be used as prophylaxis and treatment for COVID-19. Price Action: TLC shares are up 27.6% at $6.24 during the premarket session on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaTaiwan Liposome's Inhalable Liposome Formulations of Antiviral Drugs Show Promise In COVID-19© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
InspirMed Inc presented data on the potential advantages of inhalable liposome formulations of antiviral drugs at the International Society for Aerosols in Medicine Congress. InspirMed is a subsidiary of Taiwan Liposome Company (NASDAQ: TLC), specializing in developing inhalable liposome formulation programs for severe acute and chronic pulmonary diseases. Pharmacokinetic studies on inhalable liposomal GS-441524 (ISPM21) and inhalable liposomal hydroxychloroquine (ISPM19) showed significantly higher lung concentrations than their conventional counterparts, giving the candidates the potential as prophylaxis and treatment for COVID-19. GS-441524 is the main plasma metabolite of the antiviral prodrug remdesivir, which is approved in the US for COVID-19. GS-441524 holds several advantages over remdesivir, with better safety and efficacy profiles. Intratracheally administered ISPM21 had a long half-life of 22.8 hours, with significantly higher concentrations (over 200-fold) in the lung and comparable systemic exposure in the plasma than an equal dose of intravenously administered GS-441524 solution. At just 1% of the proposed oral dose of hydroxychloroquine to treat COVID-19, intratracheally administered ISPM19 had a longer half-life (around 2.5-fold) and higher exposure in the lung (~30-fold) than intravenously administered free hydroxychloroquine. ISPM19 nebulized into an aerosol exhibited a lung deposition rate (inhaled dose) of 26.67%. Price Action: TLC shares are up 3.3% at $4.4 during the premarket session on the last check Monday. See more from BenzingaClick here for options trades from BenzingaBristol Myers Unveils More Positive Data On Ulcerative Colitis Candidate ZeposiaNovavax Expands COVID-19 Vaccine Pact In South Korea© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.